BPA Call 36E79722A0004-36C26322N0466
Award Date
2/4/22
Potential Completion Date
9/30/22
Potential Value
$117K
Federal Agency
Veterans Integrated Service Network 23
Awardee
Biomarin Pharmaceutical Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Novato, CA 94949, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 19 awarded a delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule to Biomarin Pharmaceutical Inc. for the drug PALYNZIQ. With a potential value of $0.00, this firm fixed price order has a completion date of July 29, 2021. Placed under Master GSA Schedule FSS-61-IB and with performance in San Anselmo, California, this non-set aside award provides the drug to support...
This federal contract award is for the delivery of the pharmaceutical product ORLADEYO (berotralstat) to the Department of Veterans Affairs (VA) through the Veterans Integrated Service Network 20 (VISN 20). The prime contractor is Biocryst Pharmaceuticals Inc., a biotechnology company that specializes in developing small molecule drugs for rare diseases. The contract is a delivery order under Biocryst's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs, which has a ceiling...
This federal contract award is for a delivery order under Biocryst Pharmaceuticals Inc.'s Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) with the U.S. Department of Veterans Affairs (VA). The award, valued at $387,618.82, is for the bulk ordering of ORLADEYO, a medication used to treat hereditary angioedema. The contract has an ultimate completion date of March 11, 2025. Biocryst Pharmaceuticals is a biotechnology company that specializes in developing small...
This federal contract award, valued at $43,476.60, was issued by the Department of Veterans Affairs (VA) to Biogen U.S. Corporation, a pharmaceutical and biotechnology company. The contract is a firm-fixed-price delivery order placed against Biogen's Pharmaceuticals and Drugs General Services Administration (GSA) Schedule contract. The contract is for the delivery of QALSODY (tofersen), a pharmaceutical product used to treat neurological conditions in veterans. This award does not carry a...
This federal contract award is for the delivery of TARPEYO, a specialized pharmaceutical product, to the Department of Veterans Affairs (VA). The prime contractor, Calliditas Therapeutics US Inc., is a foreign-owned, for-profit pharmaceutical company that has established itself as a key supplier of TARPEYO to VA medical centers and clinics nationwide. The contract, awarded on March 12, 2024, is a delivery order under Calliditas Therapeutics US Inc.'s Federal Supply Schedule (FSS) contract for...
<p>The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 7 awarded a Firm Fixed Price BPA Call contract to Shire US Inc., a foreign-owned, for-profit manufacturer of goods, for the delivery of the drug Cinryze in August 2018. The contract, which was not set aside, had a potential value of $120,859.80 and a completion date of August 21, 2018. The contract is associated with the GSA Schedule 61-IB Pharmaceuticals and Drugs.</p>
This is a firm fixed-price delivery order award to Travere Therapeutics, Inc., a biopharmaceutical company, by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 21. The contract is for the supply of Travere's specialty pharmaceutical product Filspari 400mg, which is used to treat rare diseases affecting kidney and liver function. The award has a ceiling value of $7,354.26 and a period of performance through September 30, 2024. Travere Therapeutics holds a Federal Supply...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 7 awarded a Blanket Purchase Agreement (BPA) call to Shire US Inc., a foreign-owned, for-profit manufacturer of goods, for the express order of pharmaceuticals for May 2017 in fiscal year 2017. The contract, which was not set aside, has a firm fixed price of $104,243.40 and a completion date of May 31, 2017. The contract was awarded on May 1, 2017 under the Pharmaceuticals and Drugs Federal...
The federal contract award (ID: 36F79724D0185|36C24525N0568) is a firm fixed-price delivery order for the pharmaceutical product Galafold 123 mg, an enzyme replacement therapy used to treat Fabry disease. The contract, with a ceiling value of $21,891.21 and an ultimate completion date of April 16, 2025, was awarded to the prime contractor Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc. The contract is placed under the Pharmaceuticals and Drugs Federal Supply Schedule...
This federal contract award was issued by the Department of Veterans Affairs (VA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a prominent pharmaceutical manufacturer. The $18,803.91 firm fixed price delivery order is for the oncology medication BALVERSA 4 MG, with a completion date of June 6, 2025. The award is part of a larger $3.1 billion multiple-award Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) held by Janssen Biotech Inc. with...